NCT06207175 2024-01-23
A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 3 Unknown
Clinical Trials
9 trialsNCT05986981 2023-08-14
MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04704908 2023-01-26
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)
Xiamen University
Unknown
NCT04969445 2023-01-26
The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
Xiamen University
Unknown
NCT05045755 2023-01-26
The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
Xiamen University
Unknown
NCT05672966 2023-01-06
Phase I Clinical Trial of a Candidate HPV Vaccine
Wuhan BravoVax Co., Ltd.
Phase 1 Unknown
NCT05668572 2023-01-04
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 3 Unknown
NCT03525652 2018-05-16
Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment
The First Affiliated Hospital of Guangdong Pharmaceutical University
Phase 1/2 Unknown
NCT01512784 2012-01-19
Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults
University of Milan
Phase 3 Unknown